Tropomyosin receptor kinase (TRK) biology and the role of NTRK gene fusions in cancer

被引：184
|
作者：
Amatu, A. [1 ]
Sartore-Bianchi, A. [1 ,2 ]
Bencardino, K. [1 ]
Pizzutilo, E. G. [1 ,2 ]
Tosi, F. [1 ,2 ]
Siena, S. [1 ,2 ]
机构：
[1] Grande Osped Metropolitano Niguarda, Niguarda Canc Ctr, Dept Hematol & Oncol, Piazza Osped Maggiore 3, I-20162 Milan, Italy
[2] Univ Milan, Dept Oncol & Hematooncol, Milan, Italy
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
基金：
欧盟地平线“2020”;
关键词：
TRK; tropomyosin receptor kinase; NTRK gene fusions; TRK fusion cancer; NERVE GROWTH-FACTOR; TYROSINE PROTEIN-KINASE; NEUROTROPHIC FACTOR; MESOBLASTIC NEPHROMA; TARGETED THERAPY; CONGENITAL INSENSITIVITY; INHIBITOR ENTRECTINIB; PROTOONCOGENE PRODUCT; ACQUIRED-RESISTANCE; HIGH-FREQUENCY;
D O I：
10.1093/annonc/mdz383
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The tropomyosin receptor kinase (TRK) family of receptor tyrosine kinases are encoded by NTRK genes and have a role in the development and normal functioning of the nervous system. Since the discovery of an oncogenic NTRK gene fusion in colorectal cancer in 1986, over 80 different fusion partner genes have been identified in a wide array of adult and paediatric tumours, providing actionable targets for targeted therapy. This review describes the normal function and physiology of TRK receptors and the biology behind NTRK gene fusions and how they act as oncogenic drivers in cancer. Finally, an overview of the incidence and prevalence of NTRK gene fusions in various types of cancers is discussed.
引用
收藏
页码：VIII5 / VIII15
页数：11
相关论文
共 50 条
  • [31] Efficacy and safety of larotrectinib in a pooled analysis of patients (Pts) with tropomyosin receptor kinase (TRK) fusion cancer
    Drilon, A.
    Shen, L.
    van Tilburg, C.
    Doz, F.
    Tan, D. S. W.
    Lin, J. J.
    Kummar, S.
    Lassen, U. N.
    McDermott, R. S.
    Dierselhuis, M. P.
    Albert, C. M.
    Nagasubramanian, R.
    Watt, T.
    Patil, T.
    Burcoveanu, D-I.
    Norenberg, R.
    Brega, N.
    Laetsch, T. W.
    Xu, R-H.
    Hong, D. S.
    ANNALS OF ONCOLOGY, 2023, 34 : S470 - S470
  • [32] NTRK Gene Fusions in Solid Tumors and TRK Inhibitors: A Systematic Review of Case Reports and Case Series
    Iannantuono, Giovanni Maria
    Riondino, Silvia
    Sganga, Stefano
    Rosenfeld, Roberto
    Guerriero, Simona
    Carlucci, Manuela
    Capotondi, Barbara
    Torino, Francesco
    Roselli, Mario
    JOURNAL OF PERSONALIZED MEDICINE, 2022, 12 (11):
  • [33] Efficacy and Safety of Larotrectinib in Patients With Tropomyosin Receptor Kinase (TRK) Fusion-Positive Lung Cancer
    Drilon, A.
    Lin, J.
    Lassen, U.
    Leyvraz, S.
    Liu, Y.
    Patel, J.
    Rosen, L.
    Solomon, B.
    Norenberg, R.
    Dima, L.
    Brega, N.
    Shen, L.
    Moreno, V.
    Kummar, S.
    Tan, D.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1125 - S1126
  • [34] Updated efficacy and safety of larotrectinib in patients with tropomyosin receptor kinase (TRK) fusion lung cancer.
    Drilon, Alexander E.
    Lin, Jessica Jiyeong
    Kummar, Shivaani
    Tan, Daniel Shao-Weng
    Patel, Jyoti D.
    Lassen, Ulrik Niels
    Leyvraz, Serge
    Moreno, Victor
    Rosen, Lee S.
    Solomon, Benjamin Maurice
    Yachnin, Jeffrey
    Liu, Yongmei
    Dai, Ming-Shen
    Norenberg, Ricarda
    Fellous, Marc Mardoche
    Mussi, Chiara Erminia
    Shen, Lin
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [35] Insights into Current Tropomyosin Receptor Kinase (TRK) Inhibitors: Development and Clinical Application
    Yan, Wei
    Lakkaniga, Naga Rajiv
    Carlomagno, Francesca
    Santoro, Massimo
    McDonald, Neil Q.
    Lv, Fengping
    Gunaganti, Naresh
    Frett, Brendan
    Li, Hong-yu
    JOURNAL OF MEDICINAL CHEMISTRY, 2019, 62 (04) : 1731 - 1760
  • [36] Pan-tropomyosin receptor kinase immunohistochemistry is a feasible routine screening strategy for NTRK fusions in mismatch repair-deficient colorectal carcinomas
    Zhang, Zijuan
    Pang, Junyi
    Chen, Longyun
    Chen, Jingci
    Li, Junjie
    Liu, Hangqi
    Wang, Jing
    Wu, Huanwen
    Liang, Zhiyong
    HUMAN PATHOLOGY, 2022, 129 : 21 - 31
  • [37] Long-term efficacy and safety of larotrectinib in patients with tropomyosin receptor kinase (TRK) fusion lung cancer
    Rieke, D. T.
    Lin, Iyeong J.
    Tan, D. S.
    Kummar, S.
    Patel, J. D.
    Cermignani, L.
    Dai, M. -S.
    Lassen, U. N.
    Leyvraz, S.
    Liu, Y.
    Moreno, V.
    Rosen, L.
    Saada-Bouzid, E.
    Solomon, B.
    Xu, R. -H.
    Yachnin, J.
    Norenberg, R.
    Burcoveanu, D. -I.
    Mussi, C. E.
    Shen, L.
    Drilon, A.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 9 - 10
  • [38] Role Of Truncated Tropomyosin Receptor Kinase B In Oral Cancer Pain
    Merlo, Jaclyn
    Ibrahim, Tarek
    Wu, Ping
    Ruparel, Shivani
    JOURNAL OF PAIN, 2024, 25 (04): : 20 - 21
  • [39] Long-term efficacy and safety of larotrectinib in patients with tropomyosin receptor kinase (TRK) fusion lung cancer
    Lin, Jessica Jiyeong
    Tan, Daniel Shao-Weng
    Kummar, Shivaani
    Patel, Jyoti D.
    Cermignani, Luciano
    Dai, Ming-Shen
    Lassen, Ulrik Niels
    Leyvraz, Serge
    Liu, Yongmei
    Moreno, Victor
    Rosen, Lee S.
    Saada-Bouzid, Esma
    Solomon, Benjamin Maurice
    Xu, Rui-Hua
    Yachnin, Jeffrey
    Norenberg, Ricarda
    Burcoveanu, Domnita-Ileana
    Mussi, Chiara E.
    Shen, Lin
    Drilon, Alexander E.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [40] ACTIVITY OF LAROTRECTINIB IN TROPOMYOSIN RECEPTOR KINASE (TRK) FUSION CANCER PATIENTS WITH CENTRAL NERVOUS SYSTEM (CNS) METASTASES
    Patel, Jyoti D.
    Farago, Anna F.
    Hong, David S.
    Lassen, Ulrik N.
    Leyvraz, Serge
    Park, Keunchil
    Sohal, Davendra P. S.
    Solomon, Benjamin
    Reeves, John A.
    Dima, Laura
    Brega, Nicoletta
    Drilon, Alexander
    NEURO-ONCOLOGY, 2020, 22 : 41 - 42
12345